CCL3 and plasma cell myeloma: Next, we tested whether A/B DNA vaccines encoding vaccine protein with either one or two MIP1α-targeting units differed in their ability to induce antigen-specific IgG1 and IgG2a responses against the scFv315 multiple myeloma antigen that was bivalently expressed (on both A and B arms).